Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9492034 | 0.85 | FDPS (0.45) | POLBL3MBTL1CYP3A4SMPD1 | |
| SCHEMBL4068245 | 0.83 | SMPD1 (0.47) | SMPD1 | |
| SCHEMBL17577640 | 0.81 | FDPS (0.36) | POLBTSHRTP53TDP1 | |
| SCHEMBL4459817 | 0.81 | PPARD (0.42) | POLBGAAL3MBTL1TSHRCYP3A4 | |
| SCHEMBL9652011 | 0.79 | FDPS (0.38) | POLBTSHRTP53TDP1 | |
| SCHEMBL2821620 | 0.78 | POLB (0.44) | POLBGAAL3MBTL1TSHRCYP3A4 | |
| SCHEMBL4453625 | 0.76 | PPARD (0.45) | POLBGAAL3MBTL1TSHRCYP3A4 | |
| SCHEMBL17576905 | 0.75 | FDPS (0.32) | POLBTSHR | |
| SCHEMBL15981052 | 0.75 | TSHR (0.37) | POLBTSHRTP53TDP1 | |
| SCHEMBL20558035 | 0.73 | POLB (0.47) | POLBGAAL3MBTL1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102639153-B | Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents | 通用电气公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9205155-B2 | Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents | GENERAL ELECTRIC COMPANY (US) | 2015-12-08 | — | — | US | disclosed |
| WO-2011051422-A2 | TREATING WATER INSOLUBLE NANOPARTICLES WITH HYDROPHILIC ALPHA-HYDROXYPHOSPHONIC ACID CONJUGATES, THE SO MODIFIED NANOPARTICLES AND THEIR USE AS CONTRAST AGENTS | GENERAL ELECTRIC COMPANY (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20110104072-A1 | TREATING WATER INSOLUBLE NANOPARTICLES WITH HYDROPHILIC ALPHA-HYDROXYPHOSPHONIC ACID CONJUGATES, THE SO MODIFIED NANOPARTICLES AND THEIR USE AS CONTRAST AGENTS | GENERAL ELECTRIC COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104072-A1 | TREATING WATER INSOLUBLE NANOPARTICLES WITH HYDROPHILIC ALPHA-HYDROXYPHOSPHONIC ACID CONJUGATES, THE SO MODIFIED NANOPARTICLES AND THEIR USE AS CONTRAST AGENTS | HAMP, SLC46A1, CD44 | POLB 2852/4885GAA 335/4885L3MBTL1 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.